|
| 產(chǎn)地 | 進(jìn)口、國(guó)產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號(hào) | CS9928 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:50-200 |
| CAS編號(hào) | |
| 抗體名 | Anti-Hepatitis C Virus RNA-directed RNA polymerase |
| 克隆性 | |
| 靶點(diǎn) | 詳見說(shuō)明書 |
| 適應(yīng)物種 | 詳見說(shuō)明書 |
| 形態(tài) | 詳見說(shuō)明書 |
| 宿主 | 詳見說(shuō)明書 |
| 亞型 | IgG |
| 標(biāo)識(shí)物 | 詳見說(shuō)明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from Hepatitis C Virus RNA-directed RNA polymerase |
NS4B（65kDa）抗體說(shuō)明書 英文名稱 Anti-Hepatitis C Virus RNA-directed RNA polymerase
中文名稱 NS4B（65kDa）抗體說(shuō)明書
別 名 RNA-directed RNA polymerase; p68; RNA dependent RNA polymerase.
產(chǎn)品屬性：
濃 度 1mg/1ml
規(guī) 格 0.1ml/100μg 0.2ml/200μg
抗體來(lái)源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) HCV
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 細(xì)菌及
蛋白分子量 predicted molecular weight: 65kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from Hepatitis C Virus RNA-directed RNA polymerase
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
NS4B（65kDa）抗體說(shuō)明書 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:50-200
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 HCV is a positive, single-stranded RNA virus in the Flaviviridae family. The genome is approximately 10,000 nucleotides and encodes a single polyprotein of about 3,000 amino acids. The polyprotein is processed by host cell and viral proteases into three major structural proteins, and several non-structural proteins necessary for viral replication, of which NS5B is one. NS5B RNA-dependant RNA polymerase is responsible for replication of the hepatitis C viral genome, and is currently a principal target for chemotherapeutic inhibition of HCV replication. Hepatitis C virus (HCV) can cause chronic hepatitis, cirrhosis and hepatocellular carcinoma. At present there is no vaccine effective against HCV. Host membrane insertion occurs after processing by the NS3 protease.
Function : Core protein packages viral RNA to form a viral nucleocapsid, and promotes virion budding. Modulates viral translation initiation by interacting with HCV IRES and 40S ribosomal subunit. Also regulates many host cellular functions such as signaling pathways and apoptosis. Prevents the establishment of cellular antiviral state by blocking the interferon-alpha/beta (IFN-alpha/beta) and IFN-gamma signaling pathways and by inducing human STAT1 degradation. Thought to play a role in virus-mediated cell transformation leading to hepatocellular carcinomas. Interacts with, and activates STAT3 leading to cellular transformation. May repress the promoter of p53, and sequester CREB3 and SP110 isoform 3/Sp110b in the cytoplasm. Also represses cell cycle negative regulating factor CDKN1A, thereby interrupting an important check point of normal cell cycle regulation. Targets transcription factors involved in the regulation of inflammatory responses and in the immune response: suppresses NK-kappaB activation, and activates AP-1. Could mediate apoptotic pathways through association with TNF-type receptors TNFRSF1A and LTBR, although its effect on death receptor-induced apoptosis remains controversial. Enhances TRAIL mediated apoptosis, suggesting that it might play a role in immune-mediated liver cell injury. Seric core protein is able to bind C1QR1 at the T-cell surface, resulting in down-regulation of T-lymphocytes proliferation. May transactivate human MYC, Rous sarcoma virus LTR, and SV40 promoters. May suppress the human FOS and HIV-1 LTR activity. Alters lipid metabolism by interacting with hepatocellular proteins involved in lipid accumulation and storage. Core protein induces up-regulation of FAS promoter activity, and thereby probably contributes to the increased triglyceride accumulation in hepatocytes (steatosis).E1 and E2 glycoproteins form a heterodimer that is involved in virus attachment to the host cell, virion internalization through clathrin-dependent endocytosis and fusion with host membrane. E1/E2 heterodimer binds to human LDLR, CD81 and SCARB1/SR-BI receptors, but this binding is not sufficient for infection, some additional liver specific cofactors may be needed. The fusion function may possibly be carried by E1. E2 inhibits human EIF2AK2/PKR activation, preventing the establishment of an antiviral state. E2 is a viral ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on liver sinusoidal endothelial cells and macrophage-like cells of lymph node sinuses. These interactions allow capture of circulating HCV particles by these cells and subsequent transmission to permissive cells. DCs act as sentinels in various tissues where they entrap pathogens and convey them to local lymphoid tissue or lymph node for establishment of immunity. Capture of circulating HCV particles by these SIGN+ cells may facilitate virus infection of proximal hepatocytes and lymphocyte subpopulations and may be essential for the establishment of persistent infection.P7 seems to be a heptameric ion channel protein (viroporin) and is inhibited by the antiviral drug amantadine. Also inhibited by long-alkyl-chain iminosugar derivatives. Essential for infectivity.Protease NS2-3 is a cysteine protease responsible for the autocatalytic cleavage of NS2-NS3. Seems to undergo self-inactivation following maturation.NS3 displays three enzymatic activities: serine protease, NTPase and RNA helicase. NS3 serine protease, in association with NS4A, is responsible for the cleavages of NS3-NS4A, NS4A-NS4B, NS4B-NS* and NS*-NS5B. NS3/NS4A complex also prevents phosphorylation of human IRF3, thus preventing the establishment of dsRNA induced antiviral state. NS3 RNA helicase binds to RNA and unwinds dsRNA in the 3' to 5' direction, and likely RNA stable secondary structure in the template strand. Cleaves and inhibits the host antiviral protein MAVS.NS4B induces a specific membrane alteration that serves as a scaffold for the virus replication complex. This membrane alteration gives rise to the so-called ER-derived membranous web that contains the replication complex.NS* is a component of the replication complex involved in RNA-binding. Its interaction with Human VAPB may target the viral replication complex to vesicles. Down-regulates viral IRES translation initiation. Mediates interferon resistance, presumably by interacting with and inhibiting human EIF2AK2/PKR. Seems to inhibit apoptosis by interacting with BIN1 and FKBP8. The hyperphosphorylated form of NS* is an inhibitor of viral replication.NS5B is a RNA-dependent RNA polymerase that plays an essential role in the virus replication.Subunit : Core protein is a homomultimer that binds the C-terminal part of E1 and interacts with numerous cellular proteins. Interaction with human STAT1 SH2 domain seems to result in decreased STAT1 phosphorylation, leading to decreased IFN-stimulated gene transcription. In addition to blocking the formation of phosphorylated STAT1, the core protein also promotes ubiquitin-mediated proteasome-dependent degradation of STAT1. Interacts with, and constitutively activates human STAT3. Associates with human LTBR and TNFRSF1A receptors and possibly induces apoptosis. Binds to human SP110 isoform 3/Sp110b, HNRPK, C1QR1, YWHAE, UBE3A/E6AP, DDX3X, APOA2 and RXRA proteins. Interacts with human CREB3 nuclear transcription protein, triggering cell transformation. May interact with human p53. Also binds human cytokeratins KRT8, KRT18, KRT19 and VIM (vimentin). E1 and E2 glycoproteins form a heterodimer that binds to human LDLR, CLDN1, CD81 and SCARB1 receptors. E2 binds and inhibits human EIF2AK2/PKR. Also binds human CD209/DC-SIGN and CLEC4M/DC-SIGNR. p7 forms a homoheptamer in vitro. NS2 forms a homodimer containing a pair of composite active sites at the dimerization interface. NS2 seems to interact with all other non-structural (NS) proteins. NS4A interacts with NS3 serine protease and stabilizes its folding. NS3-NS4A complex is essential for the activation of the latter and allows membrane anchorage of NS3. NS3 interacts with human TANK-binding kinase TBK1 and MAVS. NS4B and NS* form homodimers and seem to interact with all other non-structural (NS) proteins. NS* also interacts with human EIF2AK2/PKR, FKBP8, GRB2, BIN1, PIK3R1, SRCAP, VAPB and with most Src-family kinases. NS5B is a homooligomer and interacts with human VAPB, HNRNPA1 and SEPT6.Subcellular Location : RNA-directed RNA polymerase: Host endoplasmic reticulum membrane; Single-pass type I membrane protein (Potential). Note=Host membrane insertion occurs after processing by the NS3 protease.Post-translational modifications : Specific enzymatic cleavages in vivo yield mature proteins. The structural proteins, core, E1, E2 and p7 are produced by proteolytic processing by host signal peptidases. The core protein is synthesized as a 21 kDa precursor which is retained in the ER membrane through the hydrophobic signal peptide. Cleavage by the signal peptidase releases the 19 kDa mature core protein. The other proteins (p7, NS2-3, NS3, NS4A, NS4B, NS* and NS5B) are cleaved by the viral proteases.Envelope E1 and E2 glycoproteins are highly N-glycosylated.Core protein is phosphorylated by host PKC and PKA.NS* is phosphorylated in a basal form termed p56. p58 is an hyperphosphorylated form of p56. p56 and p58 coexist in the cell in roughly equivalent amounts. Hyperphosphorylation is dependent on the presence of NS4A. Human AKT1, RPS6KB1/p70S6K, MAP2K1/MEK1, MAP2K6/MKK6 and CSNK1A1/CKI-alpha kinases may be responsible for NS* phosphorylation.NS4B is palmitoylated. This modification may play a role in its polymerization or in protein-protein interactions.The N-terminus of a fraction of NS4B molecules seems to be relocated post-translationally from the cytoplasm to the ER lumen, with a 5th transmembrane segment. The C-terminus of NS2 may be lumenal with a fourth transmembrane segment.Core protein is ubiquitinated; mediated by UBE3A and leading to core protein subsequent proteasomal degradation.Similarity : Belongs to the hepacivirus polyprotein family.Contains 1 helicase ATP-binding domain.Contains 1 peptidase C18 domain.Contains 1 peptidase S29 domain.Contains 1 RdRp catalytic domain.機(jī)理仍未十分清楚，當(dāng)HCV在肝細(xì)胞內(nèi)復(fù)制引起肝細(xì)胞結(jié)構(gòu)和功能改變或干擾肝細(xì)胞蛋白合成，可造成肝細(xì)胞變性壞死，表明HCV直接損害*，導(dǎo)致起一定作用。但多數(shù)學(xué)者認(rèn)為病理反應(yīng)可能起重要作用，發(fā)現(xiàn)肝炎與一樣，其組織浸潤(rùn)細(xì)胞以CD3+為主，細(xì)胞毒T細(xì)胞（TC）特異攻擊HCV感染的靶細(xì)胞，可引起肝細(xì)胞損傷。
實(shí)驗(yàn)流程：
全、新、優(yōu)、品、好四大特點(diǎn)：
NS4B（65kDa）抗體說(shuō)明書 全：公司提供上萬(wàn)種產(chǎn)品，涵蓋了生物試劑，elisa試劑盒，標(biāo)準(zhǔn)品，培養(yǎng)基，原裝耗材，抗體、培養(yǎng)基、ATCC細(xì)胞等，基本上各種科研所需產(chǎn)品在我司都能找到。
新：產(chǎn)品更新速度較快，基本上每周都有新產(chǎn)品出現(xiàn)。
優(yōu)：產(chǎn)品質(zhì)量好，投訴比較少。
好：我公司具有優(yōu)質(zhì)的技術(shù)團(tuán)隊(duì)，產(chǎn)品一旦售出，實(shí)驗(yàn)過(guò)程中遇到困難可提供在線技術(shù)咨詢。使您使用產(chǎn)品時(shí)沒(méi)有任何的后顧之憂。
正在熱銷的相關(guān)產(chǎn)品：
LBP(Human lipolysaccharide binding protein) ELISA Kit 人脂多糖結(jié)合蛋白Multi-class antibodies規(guī)格： 48T
Anti-TPSB2 肥大細(xì)胞類胰蛋白酶β2Multi-class antibodies規(guī)格： 0.1ml
Rhesus antibody Rh Junctophilin 4 連接蛋白JPH4抗體 規(guī)格 0.2ml
IL-9 ELISA Kit 大鼠白介素9 96T
Proteasome 20S beta 3 英文名稱： 蛋白酶體PSMβ3抗體 0.2ml
C4orf29 英文名稱： 4號(hào)染色體開放閱讀框29抗體 0.2ml
Anti-TPSB2 肥大細(xì)胞類胰蛋白酶β2Multi-class antibodies規(guī)格： 0.1ml
PSA(Mouse prostate specific antigen) ELISA Kit 小鼠特異性抗原Multi-class antibodies規(guī)格： 48T
Anti-CD158b2/KIR2DL3/NKAT2a/FITC 熒光素標(biāo)記NK細(xì)胞抑制性受體2DL3抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh Donkey Anti-human IgG/RBITC 羅丹明標(biāo)記的驢抗人IgG 規(guī)格 0.1ml
HBcAb(IgM) 核心抗體 IgM 96T
MRGX1 英文名稱： G蛋白偶聯(lián)受體MRGX1抗體 0.1ml
AIP1 英文名稱： 激活素受體相互作用蛋白1抗體 0.2ml
Anti-CD158b2/KIR2DL3/NKAT2a/FITC 熒光素標(biāo)記NK細(xì)胞抑制性受體2DL3抗體IgGMulti-class antibodies規(guī)格： 0.2ml
PLAUR/uPAR(Human Urokinase-type Plasminogen Activator Receptor) ELISA kit 人尿激酶型纖溶酶原激活物受體Multi-class antibodies規(guī)格： 48T
Anti-Omgp 少突細(xì)胞髓磷脂糖蛋白抗體Multi-class antibodies規(guī)格： 0.1ml
Rhesus antibody Rh ID4 DNA結(jié)合抑制因子4抗體 規(guī)格 0.1ml
LSP(Human liver specific lipoprotein) ELISA Kit 人抗肝特異性脂蛋白抗體 96T
PIM3 英文名稱： 絲酸/蘇酸蛋白激酶PIM3抗體 0.2ml
C17orf97 英文名稱： 17號(hào)染色體開放閱讀框97抗體 0.2ml
Anti-Omgp 少突細(xì)胞髓磷脂糖蛋白抗體Multi-class antibodies規(guī)格： 0.1ml
煌綠黃胺嘧啶瓊脂250g用于沙門氏的分離培養(yǎng)
ISP培養(yǎng)基 250g 用于鏈霉菌的培養(yǎng)
改良Camp-BAP氏瓊脂基礎(chǔ) Camp-BAP Agar Base,Modified 250 用于彎曲桿菌選擇性分離培養(yǎng)(GB標(biāo)準(zhǔn))
胰蛋白胨大豆肉湯(TSB)250g/瓶用于細(xì)菌的增菌、培養(yǎng)incubationmedia胰蛋白胨大豆肉湯(TSB)250g/瓶用于細(xì)菌的增菌、培養(yǎng)
HE瓊脂平板(9cm) 10個(gè)/包 用于沙門氏菌的選擇性分離培養(yǎng)
金氏B培養(yǎng)基(KBA)250g用于檢測(cè)假單胞菌的熒光素
金氏B培養(yǎng)基 King’s B medium 用于銅綠假單菌產(chǎn)熒光色素試驗(yàn)
乳酸菌選擇性培養(yǎng)基 Raka-Ray Medium 250克 啤酒中乳酸菌檢測(cè)和分離培養(yǎng)
標(biāo)準(zhǔn)II號(hào)營(yíng)養(yǎng)瓊脂250細(xì)菌計(jì)數(shù)、不含糖，可作血瓊脂基礎(chǔ)和傳代用(MERCK方法)incubationmedia標(biāo)準(zhǔn)II號(hào)營(yíng)養(yǎng)瓊脂250細(xì)菌計(jì)數(shù)、不含糖，可作血瓊脂基礎(chǔ)和傳代用(MERCK方法)
膽硫乳瓊脂(DHL) 250g 腸道菌選擇性培養(yǎng)基，特別是沙門氏菌的選擇性分離(GB、SN標(biāo)
NS4B（65kDa）抗體說(shuō)明書 BD測(cè)試包 規(guī)格： 個(gè) 用途： 評(píng)估預(yù)真空蒸汽滅菌器的空氣排除（真空）性能。預(yù)裝配的一次性測(cè)試包。滅菌后，解開包裹，取出試...
濕熱指示膠帶 規(guī)格： 18mm*55mm 用途： 將未滅菌與滅菌的物品區(qū)分開、蒸汽膠帶滅菌后由白色變?yōu)楹谏?/p>
7.0L密封培養(yǎng)灌 規(guī)格： 9.7x13.5x9.5cm 用途： 使用3.5L厭氧產(chǎn)氣劑兩袋或者2.5L厭氧產(chǎn)氣劑三袋；可裝42個(gè)培養(yǎng)皿。
2.5L密封培養(yǎng)灌 規(guī)格： 19.7x13.5x9.5cm 用途： 使用2.5L厭氧產(chǎn)氣劑一袋；可裝12個(gè)培養(yǎng)皿。
技術(shù)外包服務(wù):
★NS4B（65kDa）抗體說(shuō)明書 分子生物學(xué)：質(zhì)粒抽提、PCR、Q-PCR、RT-PCR、分子生物學(xué)：基因合成、引物合成、基因測(cè)序、載體構(gòu)建等
★蛋白工程：原核、哺乳動(dòng)物蛋白表達(dá)系統(tǒng)等
★病毒包裝：腺病毒、慢病毒等
★抗體工程：磁珠分選、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等
★細(xì)胞工程：細(xì)胞表型分析(凋亡、增殖、周期、遷移、侵襲、修復(fù)、克隆形成)、細(xì)胞培養(yǎng)、細(xì)胞膜制備、穩(wěn)定細(xì)胞株構(gòu)建、細(xì)胞RNAi技術(shù)等等。
|
|
|
|
|
